These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 24010644)

  • 21. Assessing safety and efficacy of sofosbuvir for the treatment of hepatitis C.
    D'Ambrosio R; Aghemo A; Colombo M
    Expert Opin Drug Saf; 2015 Mar; 14(3):473-84. PubMed ID: 25645644
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The evolution of the therapeutic strategy in hepatitis C: features of sofosbuvir and indications.
    Alberti A; Piovesan S
    Dig Liver Dis; 2014 Dec; 46 Suppl 5():S174-8. PubMed ID: 25458777
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Sofosbuvir plus ledipasvir in combination for the treatment of hepatitis C infection.
    Bourlière M; Adhoute X; Ansaldi C; Oules V; Benali S; Portal I; Castellani P; Halfon P
    Expert Rev Gastroenterol Hepatol; 2015; 9(12):1483-94. PubMed ID: 26595560
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Antiviral therapy with nucleotide polymerase inhibitors for chronic hepatitis C.
    Kumar S; Jacobson IM
    J Hepatol; 2014 Nov; 61(1 Suppl):S91-7. PubMed ID: 25443349
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Beyond sofosbuvir: what opportunity exists for a better nucleoside/nucleotide to treat hepatitis C?
    Sofia MJ
    Antiviral Res; 2014 Jul; 107():119-24. PubMed ID: 24792751
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Sofosbuvir for the treatment of hepatitis C virus.
    Asselah T
    Expert Opin Pharmacother; 2014 Jan; 15(1):121-30. PubMed ID: 24289735
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Sofosbuvir plus daclatasvir for post-transplant recurrent hepatitis C: potent antiviral activity but no clinical benefit if treatment is given late.
    Pellicelli AM; Montalbano M; Lionetti R; Durand C; Ferenci P; D'Offizi G; Knop V; Telese A; Lenci I; Andreoli A; Zeuzem S; Angelico M
    Dig Liver Dis; 2014 Oct; 46(10):923-7. PubMed ID: 24997638
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A pilot study of triple therapy with telaprevir, peginterferon and ribavirin for elderly patients with genotype 1 chronic hepatitis C.
    Hara T; Akuta N; Suzuki F; Sezaki H; Suzuki Y; Hosaka T; Kobayashi M; Kobayashi M; Saitoh S; Kumada H
    J Med Virol; 2013 Oct; 85(10):1746-53. PubMed ID: 23861088
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacokinetics and antiviral activity of PHX1766, a novel HCV protease inhibitor, using an accelerated Phase I study design.
    Hotho DM; de Bruijne J; O'Farrell AM; Boyea T; Li J; Bracken M; Li X; Campbell D; Guler HP; Weegink CJ; Schinkel J; Molenkamp R; van de Wetering de Rooij J; van Vliet A; Janssen HL; de Knegt RJ; Reesink HW
    Antivir Ther; 2012; 17(2):365-75. PubMed ID: 22293533
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Predictive factors of virological non-response to interferon-ribavirin combination therapy for patients infected with hepatitis C virus of genotype 1b and high viral load.
    Akuta N; Suzuki F; Sezaki H; Suzuki Y; Hosaka T; Someya T; Kobayashi M; Saitoh S; Watahiki S; Sato J; Kobayashi M; Arase Y; Ikeda K; Kumada H
    J Med Virol; 2006 Jan; 78(1):83-90. PubMed ID: 16299715
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A novel promising therapeutic option against hepatitis C virus: an oral nucleotide NS5B polymerase inhibitor sofosbuvir.
    Gentile I; Borgia F; Buonomo AR; Castaldo G; Borgia G
    Curr Med Chem; 2013; 20(30):3733-42. PubMed ID: 23848533
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antiviral activity of TMC435 monotherapy in patients infected with HCV genotypes 2-6: TMC435-C202, a phase IIa, open-label study.
    Moreno C; Berg T; Tanwandee T; Thongsawat S; Van Vlierberghe H; Zeuzem S; Lenz O; Peeters M; Sekar V; De Smedt G
    J Hepatol; 2012 Jun; 56(6):1247-53. PubMed ID: 22326470
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Safety and efficacy of sofosbuvir-based treatment of acute hepatitis C in end-stage renal disease patients undergoing haemodialysis.
    He YL; Yang SJ; Hu CH; Dong J; Gao H; Yan TT; Liu JF; Yang Y; Ren DF; Zhu L; Zhao YR; Chen TY
    Aliment Pharmacol Ther; 2018 Feb; 47(4):526-532. PubMed ID: 29250808
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Case report of successful treatment of fibrosing cholestatic hepatitis C with sofosbuvir and ribavirin after liver transplantation.
    Kim B; Trivedi A; Thung SN; Grewal P
    Semin Liver Dis; 2014 Feb; 34(1):108-12. PubMed ID: 24782264
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dual oral therapy with daclatasvir and asunaprevir for patients with HCV genotype 1b infection and limited treatment options.
    Suzuki Y; Ikeda K; Suzuki F; Toyota J; Karino Y; Chayama K; Kawakami Y; Ishikawa H; Watanabe H; Hu W; Eley T; McPhee F; Hughes E; Kumada H
    J Hepatol; 2013 Apr; 58(4):655-62. PubMed ID: 23183526
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Randomised clinical trial: anti-viral activity of ANA773, an oral inducer of endogenous interferons acting via TLR7, in chronic HCV.
    Bergmann JF; de Bruijne J; Hotho DM; de Knegt RJ; Boonstra A; Weegink CJ; van Vliet AA; van de Wetering J; Fletcher SP; Bauman LA; Rahimy M; Appleman JR; Freddo JL; Janssen HL; Reesink HW
    Aliment Pharmacol Ther; 2011 Aug; 34(4):443-53. PubMed ID: 21707679
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacokinetics and pharmacodynamics of sofosbuvir and ledipasvir for the treatment of hepatitis C.
    Cuenca-Lopez F; Rivero A; Rivero-Juárez A
    Expert Opin Drug Metab Toxicol; 2017 Jan; 13(1):105-112. PubMed ID: 27797596
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A pilot study of combination therapy with initial high-dose interferon and amantadine hydrochloride for patients with chronic hepatitis C with the genotype 1b virus.
    Uyama H; Enomoto H; Kishima Y; Yamamoto M; Yoshida K; Okuda Y; Hirotani T; Kuroda T; Ito H; Matsuda M; Terabayashi M; Noguchi S; Kawase I; Nakamura H
    Hepatogastroenterology; 2003; 50(54):2112-6. PubMed ID: 14696476
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Safety analysis of sofosbuvir and ledipasvir for treating hepatitis C.
    Fazel Y; Lam B; Golabi P; Younossi Z
    Expert Opin Drug Saf; 2015 Aug; 14(8):1317-26. PubMed ID: 26043900
    [TBL] [Abstract][Full Text] [Related]  

  • 40. GS-9669: a novel non-nucleoside inhibitor of viral polymerase for the treatment of hepatitis C virus infection.
    Gentile I; Buonomo AR; Zappulo E; Coppola N; Borgia G
    Expert Rev Anti Infect Ther; 2014 Oct; 12(10):1179-86. PubMed ID: 25096404
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.